1. Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
   Jie Zhou et al, 2018, Seminars in Immunology CrossRef
2. Inflammatory cell indexes as preoperative predictors of hospital stay in open elective thoracic surgery
   Panagiotis Paliogiannis et al, 2018, ANZ Journal of Surgery CrossRef
3. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
   Carlo Putzu et al, 2018, Cancer Immunol Immunother CrossRef
4. Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients’ selection
   Giuseppe Luigi Banna et al, 2018, Critical Reviews in Oncology/Hematology CrossRef
5. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice
   Passiglia Francesco et al, 2018, Future Oncology CrossRef
6. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies
   Dedong Cao et al, 2018, OncoImmunology CrossRef
7. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
   Won Jin Ho et al, 2018, j. immunotherapy cancer CrossRef
8. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor  in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy
   Dong Guo et al, 2018, Future Oncology CrossRef
9. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
   David Aguiar-Bujanda et al, 2018, Oncol Res Treat CrossRef
10. Role of preoperative blood markers as prognostic factors for lung cancer surgery
    Umar Imran Hamid et al, 2019, Asian Cardiovasc Thorac Ann CrossRef
11. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
    Francesco Passiglia et al, 2019, Ther Adv Med Oncol CrossRef
12. Predicting Success of Two-Stage Exchange for Prosthetic Joint Infection Using C-Reactive Protein/Albumin Ratio
    Cierra S. Hong et al, 2019, Advances in Orthopedics CrossRef
13. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
    Ufuk Yılmaz et al, 2018, Indian J Cancer CrossRef
14. The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease
    Zengpanpan Ye et al, 2019, Medicine CrossRef
15. Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors
    Muhammad Z. Afzal et al, 2019, Journal of Immunotherapy CrossRef
16. Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC
    null Ercetin et al, 2019, Cancers CrossRef
17. Neutrophil‐to‐lymphocyte ratio and risk of lung cancer mortality in a low‐risk population: A cohort study
    Jihoon Kang et al, 2019, Int. J. Cancer CrossRef
18. Frailty in Older Patients Referred to Oncology, and Impact of Treatment: Use of a Modified 6 Item Score
    Bridget Robinson et al, 2019, COR CrossRef
19. Prognostic value of the pretreatment albumin:globulin ratio combined with adult comorbidity evaluation 27 and TMN staging in patients with squamous cell carcinoma of the maxillary sinus
    B. Zhong et al, 2019, British Journal of Oral and Maxillofacial Surgery CrossRef
20. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
    Julia Kargl et al, 2019 CrossRef
21. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis
    Merav E. Shaul et al, 2020, FASEB j. CrossRef
22. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer
    Qing Huang et al, 2020, Medicine CrossRef
23. The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis
    Yan Lu et al, 2020, PLoS ONE CrossRef
24. The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review.
    Paulina Stefaniuk et al, 2020, Cancer Manag Res CrossRef
25. The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer
    Ali Yılmaz et al, 2020, Lung CrossRef
26. The Significance of Hematologic Indicators in the Prognosis of Patients with Advanced Lung Adenocarcinoma
    镭蓉 王, 2020, ACM CrossRef
27. Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
    Huajia Zhang et al, 2020, Pharmacology & Therapeutics CrossRef
28. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers
    Hui Xuan Lim et al, 2020, IJMS CrossRef
29. Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer
    Gordana Drpa et al, 2020 CrossRef
30. Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer
    Manman Guo et al, 2020, ATCS CrossRef
31. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies
    Meghan A. Cupp et al, 2020, BMC Med CrossRef
32. Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer
    James Newman et al, 2020, Lung Cancer Management CrossRef
33. Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers
    Laurie Grieshober et al, 2018, Cancer Prev Res CrossRef
34. Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-mutated Non-Small Cell Lung Cancer: Single Institution Analysis, Systematic Review and Meta-Analysis
    Sze Wah Samuel Chan et al, 2021, Clinical Lung Cancer CrossRef
35. Prognostic Factors Determining Survival of Patients Operated for Non-Small Cell Lung Cancer with Consideration Given to Morphological Parameters of Blood
    Mariusz Łochowski et al, 2021, CMAR CrossRef
36. Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
    Cinzia Baldessari et al, 2021, Clinical Nutrition ESPEN CrossRef
37. Systemic inflammation, TNM staging and survival in patients with lung cancer
    Ionela Erhan et al, 2020 CrossRef
38. Prognostic utility of inflammation-based biomarkers, neutrophil–lymphocyte ratio and change in neutrophil–lymphocyte ratio, in surgically resected lung cancers
    Daniel Thompson et al, 2021, Ann Thorac Med CrossRef
39. Neutrophil‐to‐Lymphocyte Ratio Predicts High‐Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma
    Emily Harding‐Theobald et al, 2021, Liver Transpl. CrossRef
40. Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer
    Laurie Grieshober et al, 2021, Cancer Causes Control CrossRef
41. Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma
    Daniel J. Gross et al, 2021, Journal of Thoracic Oncology CrossRef
42. The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Nicol Bernardinello et al, 2022, Respiratory Medicine CrossRef
43. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients
    Anne Winther-Larsen et al, 2022, BMC Cancer CrossRef
44. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer
    Alex K. Bryant et al, 2022, Lung Cancer CrossRef
45. Use of neutrophil/lymphocyte ratio (NLR) and lymphocyte/monocyte ratio (LMR) as biomarkers in the differential diagnosis of malignant solitary pulmonary nodules
    Murat Kuru et al, 2022, Med Sci Discov CrossRef
46. Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
    Ji Young Park et al, 2022, Tuberc Respir Dis CrossRef
47. Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
    Lena Gaissmaier et al, 2020, Respiration CrossRef
48. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
    Liangliang Xu et al, 2022, J Hematol Oncol CrossRef
49. Prognostic predictors of non-small cell lung cancer treated with curative resection: the role of preoperative CT texture features, clinical features, and laboratory parameters
    L. Zhou et al, 2022, Clinical Radiology CrossRef
50. Role of Polyamines as Biomarkers in Lymphoma Patients: A Pilot Study
    Donatella Coradduzza et al, 2022, Diagnostics CrossRef